Intelligent Bio Solutions Inc.

NasdaqCM INBS

Intelligent Bio Solutions Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -10.67 M

Intelligent Bio Solutions Inc. Operating Cash Flow is USD -10.67 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -56.97% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Intelligent Bio Solutions Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -6.80 M.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
SV Wall Street
NasdaqCM: INBS

Intelligent Bio Solutions Inc.

CEO Mr. Harry Simeonidis
IPO Date Dec. 23, 2020
Location United States
Headquarters 142 West 57th Street
Employees 50
Sector Healthcare
Industries
Biotechnology Autonomous Driving Clinical Trials Hardware & Electronics Medical Instruments Pharmaceuticals
Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

StockViz Staff

February 4, 2025

Any question? Send us an email